Luis Voloch and Noam Solomon (Immunai)
Stanford, Parker Institute scientists team up with two young engineers in $20M AI play with an immunology focus
Almost a year ago, a group of scientists at Stanford and the Parker Institute for Cancer Immunotherapy published a paper in Nature Medicine that challenged a common assumption about where tumor fighting cells come from: While researchers had thought that the role of checkpoint blockade was to reinvigorate T cells already present in the tumor, they suggested that the vast majority actually didn’t come from the tumor sites at all.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
